Research location
Oceanside
California, United States
Advertisement
Research activity in Oceanside
California, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 324 trials and 332 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Oceanside
324 linked trials · page 1 of 7Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight LossNCT07837973 · 2026-08-10 · 1 site observation
RECRUITING
A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive DisorderNCT07573176 · 2026-04-30 · 1 site observation
RECRUITING
A Long-Term Open-Label Study of ML-007C-MA in Adults With SchizophreniaNCT07459647 · 2026-03-31 · 1 site observation
RECRUITING
Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)NCT07379827 · 2026-02-26 · 1 site observation
RECRUITING
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using SolriamfetolNCT07484217 · 2026-02-23 · 1 site observation
RECRUITING
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive DisorderNCT07115329 · 2026-01-05 · 1 site observation
RECRUITING
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)NCT07174336 · 2025-12-22 · 1 site observation
RECRUITING
A Study to Evaluate the Effectiveness of DT-101 in Patients With DepressionNCT07300969 · 2025-12-16 · 1 site observation
RECRUITING
Efficacy of NBI-1117568 in Preventing Relapse in Adults With SchizophreniaNCT07227818 · 2025-12-16 · 1 site observation
RECRUITING
A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)NCT07196501 · 2025-08-18 · 1 site observation
RECRUITING
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With SchizophreniaNCT07114874 · 2025-07-11 · 1 site observation
RECRUITING
Randomized Withdrawal Study in Patients With SchizophreniaNCT06961968 · 2025-05-14 · 1 site observation
RECRUITING
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)NCT06966401 · 2025-04-16 · 1 site observation
RECRUITING
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung CancerNCT06890598 · 2025-03-27 · 1 site observation
RECRUITING
A Randomized Study of Azetukalner Versus Placebo in Major Depressive DisorderNCT06775379 · 2024-12-20 · 1 site observation
RECRUITING
ALTO-100 in Bipolar Disorder With Depression (BD-D)NCT06656416 · 2024-10-02 · 1 site observation
RECRUITING
Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)NCT06633016 · 2024-09-20 · 1 site observation
RECRUITING
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia SymptomsNCT06559306 · 2024-07-25 · 1 site observation
RECRUITING
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)NCT06393374 · 2024-06-24 · 1 site observation
RECRUITING
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum DisorderNCT06229210 · 2024-01-25 · 1 site observation
RECRUITING
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive SymptomsNCT06223880 · 2023-12-27 · 1 site observation
RECRUITING
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and DiabetesNCT07284901 · 2026-01-12 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have DiabetesNCT07284979 · 2025-12-30 · 1 site observation
ACTIVE_NOT_RECRUITING
Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)NCT06605105 · 2025-07-18 · 1 site observation
ENROLLING_BY_INVITATION
Study to Evaluate Efficacy and Safety of Ropanicant in MDD PatientsNCT06836063 · 2025-07-15 · 1 site observation
COMPLETED
Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar DisorderNCT07116694 · 2025-06-19 · 1 site observation
COMPLETED
Predictive Analytics and Clinical Decision Support to Improve PrEP PrescribingNCT06805877 · 2025-04-21 · 1 site observation
ACTIVE_NOT_RECRUITING
An Open-Label Study of Azetukalner in Major Depressive DisorderNCT06922110 · 2025-03-18 · 1 site observation
ENROLLING_BY_INVITATION
A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of SchizophreniaNCT06791122 · 2025-01-23 · 1 site observation
COMPLETED
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"NCT06564818 · 2024-12-17 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Test Different Doses of BI 1569912 in People With DepressionNCT06558344 · 2024-10-01 · 1 site observation
COMPLETED
Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)NCT06423781 · 2024-08-01 · 1 site observation
COMPLETED
Efficacy and Safety Study of BHV-7000 Monotherapy in Major DepressionNCT06419608 · 2024-05-28 · 1 site observation
COMPLETED
A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive MedicineNCT06280235 · 2024-03-27 · 1 site observation
COMPLETED
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive DisorderNCT06254612 · 2024-03-25 · 1 site observation
COMPLETED
PD, PK, and Safety of ALTO-203 in Patients With MDDNCT06391593 · 2024-03-25 · 1 site observation
COMPLETED
Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using SolriamfetolNCT06360419 · 2024-03-18 · 1 site observation
COMPLETED
Study to Assess the Safety and Effectiveness of NMRA-335140-501NCT06029439 · 2023-11-10 · 1 site observation
TERMINATED
Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive DisorderNCT06029426 · 2023-09-20 · 1 site observation
COMPLETED
Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of SchizophreniaNCT05838625 · 2023-03-31 · 1 site observation
COMPLETED
Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)NCT05686408 · 2023-03-02 · 1 site observation
COMPLETED
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)NCT05609968 · 2023-02-06 · 1 site observation
ACTIVE_NOT_RECRUITING
Phase 2b Study of ALTO-100 in MDDNCT05712187 · 2023-01-10 · 2 site observations
COMPLETED
A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)NCT05686239 · 2022-12-08 · 1 site observation
COMPLETED
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)NCT05658510 · 2022-11-21 · 1 site observation
COMPLETED
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)NCT05518149 · 2022-09-22 · 1 site observation
TERMINATED
A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant TherapyNCT05455684 · 2022-06-22 · 1 site observation
COMPLETED
Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124NCT05459688 · 2022-04-06 · 1 site observation
COMPLETED
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of SchizophreniaNCT05304767 · 2022-03-07 · 1 site observation
COMPLETED
A Study of CIN-107 in Patients With Uncontrolled HypertensionNCT05137002 · 2021-12-07 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.